FINWIRES · TerminalLIVE
FINWIRES

OpenText Appoints James McGourlay as President, Chief Client Officer

-- OpenText (OTEX.TO) on Monday said that James McGourlay will transition from interim chief executive officer to president, chief client officer, effective April 20, 2026.

"In this role, McGourlay will lead OpenText's global client experience, professional services, and renewals organization," said the company.

The company also said that McGourlay will report to Ayman Antoun, Chief Executive Officer of OpenText as of April 20, 2026, and will continue to serve as a member of the OpenText Executive Leadership Team. The company further said that McGourlay has held senior leadership roles across sales, customer operations, and executive management at OpenText.

"James is a proven leader with more than 30 years at OpenText, and his career has consistently been anchored in our clients and what is essential to their success," said Tom Jenkins, Executive Chairman of the Board and Chief Strategy Officer, OpenText. "As Chief Client Officer, James will strengthen client experience and renewals, support cloud adoption, and advance OpenText's position as the trusted partner for data and security for enterprise AI."

The company also announced that effective April 20, 2026, Paul Duggan will be stepping down from his position as president, chief customer officer and will continue to serve as executive vice president, special advisor. The company added that Duggan will also remain a member of the OpenText Executive Leadership Team until his departure from OpenText on July 1, 2026.

Related Articles

Asia

Dizal Pharma to Present Research Results for Three Drugs At American Society of Clinical Oncology's Annual Meeting

Dizal (Jiangsu) Pharmaceutical (SHA:688192) said it will present the latest research results of sunvozertinib tablets, golidocitinib capsules and DZD6008 at the annual meeting of the American Society of Clinical Oncology, according to a Wednesday filing on the Shanghai bourse.Sunvozertinib and DZD6008 are both developed as treatments for non-small cell lung cancer, while golidocitinib is for T-cell lymphoma. Studies has shown positive results, especially in DZD6008, which had significant antitumor activity and was safe to use.The biotechnology company's shares rose less than 2% during the midday trade.

$SHA:688192
Asia

Critica Begins Western Australia Rare Earth Project Scoping Study in the March Quarter

Critica (ASX:CRI) said the scoping study for the Jupiter rare earth project in Western Australia formally began during the March quarter, according to a Wednesday Australian bourse filing.The study integrates beneficiation, downstream processing, infrastructure, and development assumptions to define a base-case development pathway.It plans to continue and complete the 140-drill hole resource upgrade drilling at Jupiter in the June quarter. It also plans to prepare and dispatch an additional 20,000 kilograms of bulk sample for pilot-scale treatment to support ongoing optimization, performance improvement, and intermediate concentrate generation.

$ASX:CRI
Asia

North Pacific Bank Tender Offer Secures Control of Career Bank

North Pacific Bank (TYO:8524) said its tender offer for shares in Career Bank was successful, lifting its stake to 88.26% and enabling the target to become a subsidiary, according to a Wednesday filing on the Tokyo Stock Exchange.The bank acquired 852,487 shares in the offer, exceeding the minimum acceptance level required to complete the transaction.Settlement is set to begin on April 28, when Career Bank will formally be consolidated.North Pacific Bank plans to pursue procedures to make Career Bank a wholly owned unit and delist its shares from the Sapporo exchange. The acquisition cost totaled about 1.5 billion yen.

$TYO:8524